SLC35E4 inhibitors are a class of chemical compounds that selectively target and inhibit the activity of solute carrier family 35 member E4 (SLC35E4), a protein that belongs to the SLC family of transporters. The SLC family is primarily involved in transporting various substrates such as nucleotides, sugars, amino acids, and other small molecules across cellular membranes. While the specific physiological role of SLC35E4 has not been fully elucidated, it is thought to play a part in intracellular transport processes, potentially involved in moving nucleotide sugars or other critical metabolites within cellular organelles like the Golgi apparatus or endoplasmic reticulum. Inhibitors of SLC35E4 are designed to bind to key regions of the protein, preventing it from properly transporting its substrates, thus impacting the cellular processes that depend on this movement.
The development of SLC35E4 inhibitors involves in-depth research into the protein's structural and functional characteristics. Techniques such as molecular docking, computational modeling, and structural biology are employed to identify the specific binding sites where inhibitors can attach to block the transporter's function. These inhibitors are generally small molecules that are optimized for high specificity and affinity toward SLC35E4, ensuring they disrupt its function without interfering with other SLC transporters. Once synthesized, these inhibitors are evaluated through a variety of in vitro assays to measure their binding efficiency, selectivity, and ability to block substrate transport. By studying SLC35E4 inhibitors, researchers can better understand the precise role of this transporter in cellular metabolism, especially in relation to intracellular trafficking and how disruptions in these processes can affect broader metabolic pathways. Understanding the inhibition of SLC35E4 contributes to the broader knowledge of how solute carrier proteins function in regulating cellular homeostasis and substrate distribution.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Inhibits N-linked glycosylation, affecting protein folding and transport. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Inhibits Golgi mannosidase II, impacting oligosaccharide processing. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Disrupts transport between the ER and Golgi apparatus, affecting glycosylation. | ||||||
Mycophenolic acid | 24280-93-1 | sc-200110 sc-200110A | 100 mg 500 mg | $69.00 $266.00 | 8 | |
Inhibits inosine monophosphate dehydrogenase, affecting nucleotide synthesis. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Inhibits autophagy and lysosomal degradation, potentially affecting protein turnover related to SLC35E4. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
An HDAC inhibitor, which could affect gene expression, potentially influencing SLC35E4. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
An HDAC inhibitor, used in cancer therapy, might affect SLC35E4-related pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor, could impact signaling pathways, potentially affecting SLC35E4. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, which might indirectly affect proteins involved in cell growth and survival. | ||||||